TNP-2092 - Emerging Insight and Market Forecast - 2030

TNP-2092 - Emerging Insight and Market Forecast - 2030

  • February 2021 •
  • 30 pages •
  • Report ID: 6030396 •
  • Format: PDF
“TNP-2092 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Prosthetic Joint Infection in 7 Major Markets. A detailed picture of the TNP-2092 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

TNP-2092 is a multitargeting drug conjugate, exerting antibacterial activity by inhibiting three essential targets in bacterial biofilms: RNA polymerase, DNA gyrase and topoisomerase IV. TNP-2092 has demonstrated strong bactericidal activity, low frequency for development of resistance and an excellent safety profile. TNP-2092 is currently under clinical development for the treatment of prosthetic joint infections and has the potential to become the first drug approved for this indication. TenNor Therapeutics, a clinical-stage, global biopharmaceutical company has received FDA Orphan Drug Designation for TNP-2092 to treat prosthetic joint infections.

Scope of the report
The report provides insights into:
• A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug research and development activity details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around TNP-2092.
• The report contains forecasted sales for TNP-2092 till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) for Prosthetic Joint Infection.
• The report also features the SWOT analysis with analyst insights and key findings of TNP-2092.

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis ’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TNP-2092 Analytical Perspective
• In-depth TNP-2092 Market Assessment
This report provides a detailed market assessment of TNP-2092 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

• TNP-2092 Clinical Assessment
The report provides the clinical trials information of TNP-2092 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights
• In the coming years, the market scenario for Prosthetic Joint Infection is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence TNP-2092 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other emerging products for Prosthetic Joint Infection are giving market competition to TNP-2092 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of TNP-2092.
• Our in-depth analysis of the forecasted sales data of TNP-2092 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TNP-2092.

Key Questions
• Which company is developing TNP-2092 along with the phase of the clinical study?
• What is the technology utilized in the development of TNP-2092?
• What is the product type, route of administration and mechanism of action of TNP-2092?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TNP-2092 development?
• What are the key designations that have been granted to TNP-2092?
• What is the forecasted market scenario of TNP-2092?
• What is the history of TNP-2092 and what is its future?
• What is the forecasted sales of TNP-2092 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to TNP-2092?
• Which are the late-stage emerging therapies under development for the treatment of the PPD?